Risperdal, approved by the U.S. Food and Drug Administration in 1993, is an antipsychotic medication used to treat a variety of psychiatric disorders and mental health conditions, including ADD, bipolar disorder, schizophrenia.
One side effect, initially described as “rare,” is gynecomastia, or the growth and development of female breast tissue in males. There are now thousands of lawsuits around the country — more than 19,000, to be precise — alleging that use of Risperdal caused gynecomastia.
It has also been alleged that the drug maker, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, knew the full extent of the risk of gynecomastia, but failed to adequately warn patients. In late 2015, the Kentucky Attorney General settled a lawsuit against Janssen and Johnson & Johnson for $15.5 million, in which the AG alleged that the companies knew that Risperdal could cause a hormonal imbalance, resulting in breast tissue growth, but never informed patients of the significant risk.
We currently represent a young man who has developed gynecomastia after taking Risperdal, and we are preparing legal action. We are also accepting new cases. If you, a loved one, or someone else you know has been prescribed Risperdal and possibly developed breast tissue, contact us today for a free consultation and evaluation.